CONTINUE TO SITE

OR WAIT null SECS

Spotlight

View More Clinical Decision Making: Evaluating Biologics in Lupus Management Between the Lines: New Treatment Paradigms in Gout Gout Psoriatic Arthritis RA Quiz Rheumatoid Arthritis

Clinical Decision Making: Evaluating Biologics in Lupus Management Between the Lines: New Treatment Paradigms in GoutGoutPsoriatic ArthritisRA QuizRheumatoid Arthritis

Clinical

View More Arthritis COVID-19 Gout Imaging in Rheumatology Juvenile Arthritis Lupus Obesity Osteoarthritis Pediatrics Psoriasis Psoriatic Arthritis Rheumatoid Arthritis Sjogren's Syndrome Spondyloarthritis Systemic Sclerosis View More

ArthritisCOVID-19GoutImaging in RheumatologyJuvenile ArthritisLupusObesityOsteoarthritisPediatricsPsoriasisPsoriatic ArthritisRheumatoid ArthritisSjogren's SyndromeSpondyloarthritisSystemic SclerosisView More

News

All News Clinical News Industry News Practice Management

All NewsClinical NewsIndustry NewsPractice Management

Media

Expert Interviews Medical World News Podcasts Rheumatology View

Expert InterviewsMedical World NewsPodcastsRheumatology View

Conferences

Conference Coverage Conference Listing

Columns CME/CE

Resources

Clinical Guidelines Image IQ Partners Quizzes Slideshows Sponsored

Clinical GuidelinesImage IQPartnersQuizzesSlideshowsSponsored

Advertise
Contact Us
Editorial Info
Contribute
Terms and Conditions
Privacy Policy
Do not sell my Personal Information

SpotlightSee All >

Clinical Decision Making: Evaluating Biologics in Lupus Management
Between the Lines: New Treatment Paradigms in Gout
Gout
Psoriatic Arthritis
RA Quiz
Rheumatoid Arthritis

ClinicalSee All >

Arthritis
COVID-19
Gout
Imaging in Rheumatology
Juvenile Arthritis
Lupus
Obesity
Osteoarthritis
Pediatrics
Psoriasis
Psoriatic Arthritis
Rheumatoid Arthritis
Sjogren's Syndrome
Spondyloarthritis
Systemic Sclerosis
View More

Advertise
Contact Us
Editorial Info
Contribute
Terms and Conditions
Privacy Policy
Do not sell my Personal Information

Author | Frank Diamond

home

Articles

FDA Approves Additional Dose of COVID-19 Vaccine for Immunocompromised Patients

Article

The US Food and Drug Administration (FDA) announced it has authorized a third dose of either the Pfizer/BioNTech or Moderna mRNA COVID-19 vaccines for patients with compromised immune systems, such as patients with rheumatic disease.